Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report

Autor:	Juan Liu, Ben Yu, Weicheng Zheng, Wenyu Shi, Pan Hu, Yaping Zhang, Xiyue Yan
Rok vydání:	2021
Předmět:	0301 basic medicine Oncology discordant lymphoma medicine.medical_specialty Angioimmunoblastic T-cell lymphoma Combination therapy lenalidomide diffuse large B-cell lymphoma Case Report positron emission tomography/computed tomography medicine.disease_cause angioimmunoblastic T-cell lymphoma Epstein–Barr virus 03 medical and health sciences 0302 clinical medicine Maintenance therapy immune system diseases hemic and lymphatic diseases Internal medicine medicine Pharmacology (medical) Lenalidomide business.industry medicine.disease Lymphoma Regimen 030104 developmental biology 030220 oncology & carcinogenesis business Diffuse large B-cell lymphoma medicine.drug
Zdroj:	OncoTargets and therapy
ISSN:	1178-6930
Popis:	Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe the case of a 77-year-old man who was referred to the hospital because of repeated fever, night sweats, and weight loss. He was finally diagnosed with a discordant lymphoma consisting of AITL and DLBCL, with significantly different maximum standardized uptake values on positron emission tomography/computed tomography. Based on his complex illness and poor performance status, the patient received six cycles of lenalidomide combined with R-miniCHOP regimen and achieved complete remission with tolerable and controlled toxicity. He subsequently received lenalidomide maintenance therapy and achieved sustained remission. We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. Lenalidomide-combination therapy may be a preferable choice in patients with an EBV-associated discordant lymphoma.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267c6e4a7253805792378a032a3e7b67 https://doi.org/10.2147/ott.s297539 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.